Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AdimrSC-2f Vaccine in Healthy Adults
NCT05104489Phase 2Completed
- Sponsor
- Adimmune
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AdimrSC-2f in coronavirus disease 2019 (COVID-19), sponsored by Adimmune. Started Jan 2022; status: completed.
02
Drugs
AdimrSC-2f
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05104489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104489.